Clik here to view.
Foundation Medicine Advances Patient Access to Precision Medicine; Pursues...
CAMBRIDGE, Mass. Foundation Medicine, Inc. (NASDAQ:FMI) today announced that Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519), one of Japan’s leading research-based pharmaceutical companies and a...
View ArticleClik here to view.
U.S. FDA Grants Priority Review for a Supplemental New Drug Application...
NEW YORK & TOKYO Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that a supplemental New Drug Application (sNDA)...
View ArticleClik here to view.
牛津纳米孔科技有限公司宣布获得来自全球知名投资机构1亿英镑（约1.39亿美元）的投资
英国 , 牛津 牛津纳米孔科技有限公司（Oxford Nanopore Technologies...
View ArticleClik here to view.
Oxford Nanopore Announces £100 Million ($140M) Fundraising from Global Investors
OXFORD, England Oxford Nanopore Technologies Ltd, the company behind the only portable real-time DNA/RNA sequencer, MinION, has raised £100M ($140M) in new investment. Funds were raised from global...
View ArticleClik here to view.
Morinaga Milk’s New Probiotic Strain, Bifidobacterium breve A1, May Prevent...
TOKYO Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced the results of a new study investigating the preventive effects of its new probiotic...
View ArticleClik here to view.
森永乳业的新款益生菌菌株短双歧杆菌A1或可预防阿尔茨海默病发病
东京 (美国商业资讯) — 日本领先的乳制品公司森永乳业株式会社(TOKYO:2264)今天发布了一项研究成果，该研究调查该公司新款益生菌菌株短双歧杆菌A1在一个阿尔茨海默病模型中的预防效应。研究人员发现，短双歧杆菌A1可改善认知缺陷小鼠的空间识别能力以及学习和记忆能力，这表明该菌株对预防人类发生阿尔茨海默病或许有重要作用1。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Co-Diagnostics, Inc. Announces Construction Update at JV Manufacturing...
SALT LAKE CITY Co-Diagnostics, Inc. (NASDAQ: CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today an update on the Joint...
View ArticleClik here to view.
Takeda Announces Publication of Final Data from ICLUSIG® (ponatinib) Pivotal...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that final data from the pivotal Phase 2 PACE clinical trial of ICLUSIG (ponatinib) in...
View ArticleClik here to view.
AVITA Medical Announces RECELL® Health Economic Model to be Presented at...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, OTCQX: AVMXY) announced today that an abstract highlighting an economic model demonstrating the cost benefit of RECELL® in the...
View ArticleClik here to view.
武田宣布发表ICLUSIG® (ponatinib)枢纽性2期PACE血液病试验的终局数据
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE: 4502)今天宣布，《血液》杂志发表ICLUSIG (ponatinib)治疗难治性慢性粒细胞性白血病(CML)或费城染色体阳性急性淋巴细胞性白血病(Ph+...
View ArticleClik here to view.
Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation...
BOTHELL, Wash. & TOKYO Seattle Genetics, Inc. (NASDAQ: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that the U.S. Food and Drug...
View ArticleClik here to view.
BioWa、LonzaおよびTillotts Pharma AGによるPOTELLIGENT® CHOK1SV™ 技術におけるライセンス契約締結のお知らせ
東京 （ビジネスワイヤ） — 本ニュースリリースは、協和発酵キリン株式会社の米国子会社であるBioWa...
View ArticleClik here to view.
武田薬品がアイクルシグ（ポナチニブ）のピボタル第2相PACE試験から得た最終データのブラッド誌掲載を発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社(TSE: 4502)は本日、難治性の慢性骨髄性白血病（CML）またはフィラデルフィア染色体陽性急性リンパ芽球性白血病（Ph+...
View ArticleClik here to view.
Alnylam Presents New Clinical Results from the APOLLO Phase 3 Study of...
CAMBRIDGE, Mass. Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company presented new results from the APOLLO Phase 3 study of...
View ArticleClik here to view.
Toshiba Heavy-Ion Therapy System Awarded by Yonsei University Health System
KAWASAKI, Japan Toshiba Energy Systems & Solutions Corporation (Toshiba ESS), a world leader in heavy-ion therapy system, in collaboration as a consortium with DK Medical Solutions, a Korean...
View ArticleClik here to view.
MaxiNovel Pharmaceuticals, Inc. Announces FDA Orphan Drug Designation for...
GUANGZHOU, China MaxiNovel Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (“FDA”) has granted MaxiNovel Orphan Drug Designation for MAX-40279 in the treatment of...
View ArticleClik here to view.
ソウル半導体、欧州で「ヒューマンセントリック照明と健康」をテーマとするシンポジウムを開催
韓国安山市 （ビジネスワイヤ） — 世界的なLED （発光ダイオード）専業メーカーのSeoul Semiconductor Co., Ltd. (本社：韓国安山市、代表理事：李貞勲、以下「ソウル半導体」)は、光が健康と生体リズムに与える影響を、科学的、客観的に究明したシンポジウムを、世界最大級の照明展示会Light &...
View ArticleClik here to view.
サンバイオ：再生細胞薬「SB623」の開発進捗総括の更新について
東京 （ビジネスワイヤ） — 平成30年３月13日付リリース『再生細胞薬「SB623」の開発進捗総括の更新について』に記載した「SB623」の開発の進捗に動きがあり、これに伴い一部の内容を更新しました。更新箇所は下線の部分であります。 記...
View ArticleClik here to view.
SanBio: Update on Development Progress of Regenerative Cell Medicine SB623
TOKYO The SanBio Group (SanBio Co., Ltd. and subsidiary SanBio Inc.) (TOKYO:4592) has updated part of its March 13, 2018 release “Update on Development Progress of Regenerative Cell Medicine SB623”....
View ArticleClik here to view.
Cullgen Announces ALK PROTACs Publication by Its Co-founders in the European...
DOVER, Del. Cullgen Inc., a biopharmaceutical company focusing on developing new drugs using protein degradation technology today announced that the laboratories of its co-founders, Dr. Jian Jin and...
View Article